Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

Triple-negative breast cancer (TNBC) is an aggressive form of the disease that accounts for 15% of all breast cancer cases.

Dr Nidhan Biswas, the lead investigator from NIBMG, emphasised how this study moves India closer to personalised cancer care.

The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Neoadjuvant disitamab vedotin plus perioperative toripalimab has demonstrated efficacy in patients with HER2-expressing MIBC.

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...